Background: Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label study of women with human epidermal growth factor receptor 2 positive metastatic breast cancer who had documented progression on at least one T-containing regimen in the metastatic setting. This analysis focused on impact of treatments on health-related quality of life (HRQOL).
introduction
Overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene is estimated to occur in 25%-30% of all human breast cancers; HER2+ breast cancer is particularly virulent and is associated with a greater risk for disease progression and death [1] [2] [3] [4] .
Trastuzumab (Herceptin; Herceptin is the registered trade name of Genentech Inc., South San Francisco, CA), a humanized monoclonal antibody targeting the HER2 extracellular domain, was one of the first treatments approved in combination with a taxane for the first-line treatment of patients with advanced or metastatic disease whose tumors overexpress HER2 [5] . However, most patients develop resistance to trastuzumab, and their disease progresses within 1 year [6, 7] . While it is not uncommon for clinicians to continue patients on trastuzumab beyond progression, the benefit of such extended therapy is not well evaluated [8, 9] . Only recently has a study been reported evaluating the efficacy of trastuzumab beyond progression [10] .
Lapatinib [Tykerb/Tyverb; Tykerb/Tyverb are the registered trade names of GlaxoSmithKline (GSK), Research Triangle Park, NC] is an epidermal growth factor receptor inhibitor approved in the United States for use in combination with capecitabine (Xeloda; Xeloda is the registered trade name of Roche, Nutley, NJ) for the treatment of advanced or metastatic HER2-positive breast cancer in women who have received prior therapy and also for use in combination with letrozole to treat hormone-positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated. Lapatinib is established as effective treatment for HER2-positive locally advanced or metastatic breast cancer (MBC) [11] [12] [13] [14] [15] , including cancers progressing on prior trastuzumab-based therapy [11] . The positive effects of lapatinib on health-related quality of life (HRQOL) in these settings have been shown previously [16] [17] [18] [19] [20] .
In a phase III trial (EGF104900; ClinicalTrials.gov identifier: NCT00320385) of heavily pretreated patients with HER2-positive MBC progressing on trastuzumab therapy, patients taking combination lapatinib plus trastuzumab (L + T) had a statistically significant advantage over the group on lapatinib monotherapy in progression-free survival (PFS) [median PFS, 12.0 versus 8.1 weeks; P = 0.008, hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.57-0.93] [21] . An updated overall survival (OS) analysis showed a statistically significant advantage for the combination versus lapatinib monotherapy (median OS, 60.7 versus 41.4 weeks; P = 0.026, HR = 0.74; 95% CI 0.57-0.97) [22] . Both treatment regimens were generally well tolerated. Grade 1/2 diarrhea was higher in the combination arm (60% versus 48%); acneiform rash was more common in the lapatinib monotherapy arm, likely due to higher lapatinib dose. Asymptomatic decline in left ventricular ejection fraction (>20% and below the institutional normal range) occurred in 3.4% of patients in the combination arm and 1.4% of patients in lapatinib monotherapy arm; one death occurred due to cardiac toxicity in the combination arm [21] .
In addition to clinical benefits such as delayed tumor progression, increased tumor response rates, and improved survival, another goal of treating women with MBC is to provide palliation and maintain or improve their HRQOL. Since the patients had been heavily pretreated and progressed on multiple therapies in study EGF104900, it was important to investigate if additive therapy (lapatinib plus trastuzumab) compared with lapatinib alone caused any detrimental effects on HRQOL in this patient population with metastatic disease. Hence, a secondary objective of study EGF104900 was to evaluate and compare the two treatment arms with respect to HRQOL. This paper reports the results of that HRQOL evaluation.
patients and methods

clinical trial
Analyses were carried out using data from a randomized, multicenter openlabel phase III study that evaluated and compared the efficacy and tolerability of lapatinib administered in combination with trastuzumab versus lapatinib monotherapy in patients with HER2 gene-amplified MBC. Eligible patients had been adequately exposed to treatment with anthracyclines, taxanes, and trastuzumab and had documentation of disease progression on their most recent treatment, which consisted of a trastuzumab-containing regimen. All patients had measurable disease as defined by the modified RECIST. The primary end point was PFS, whereas secondary end points included OS, tumor response rate, clinical benefit, duration of response, and HRQOL.
A total of 296 patients were equally randomized to receive either oral lapatinib (1000 mg daily) plus trastuzumab (4 mg/kg i.v. load followed by 2 mg/kg i.v. weekly) or lapatinib (1500 mg daily). Treatment was administered until disease progression or withdrawal due to unacceptable toxicity or consent withdrawal. Patients receiving lapatinib monotherapy, who experienced documented radiological disease progression after at least 4 weeks of treatment, were allowed to cross over to treatment with trastuzumab plus lapatinib, remaining in the study until further disease progression was noted. Further details of study methods and efficacy/safety results have been reported previously [21, 22] . The analysis presented here uses data through 29 June 2007. quality-of-life assessments HRQOL was assessed using the Functional Assessment of Cancer TherapyBreast (FACT-B) questionnaire. The FACT-B (version 4, 1997) measures multidimensional HRQOL in patients with breast cancer [23] . It consists of a 37-item self-reporting instrument containing the 27-question Functional Assessment of Cancer Therapy-General (FACT-G) survey and a 10-question breast cancer-specific survey (measuring concerns specific to patients with breast cancer including shortness of breath, hair loss, pain, and weight change). Each question has five response options, from 0 (not at all) to 4 (very much). The FACT-B produces five subscale scores that reflect the patient's quality of life: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and a breast cancer subscale (BCS). These subscale scores are used to derive three assessment outcomes, FACT-B total score, FACT-G score, and Trial Outcome Index (TOI), which are calculated as follows:
FACT-B total score = PWB+SWB+EWB+FWB+BCS FACT-G total score = PWB+SWB+EWB+FWB TOI score = PWB+FWB+BCS As described in the scoring instructions, scores were calculated only for patients who responded to at least 80% of the items from the relevant questionnaire. A higher score in any FACT-B assessment indicates a better HRQOL. In a previous study, a minimal important difference (MID) was estimated to be 2-3 points for the BCS, 7-8 points for the FACT-B total score, and 5-6 points for the FACT-G and the TOI scores [24] .
Patients completed a FACT-B questionnaire at day 1 predose assessment and during treatment (at 4, 12, and 16 weeks, then every 8 weeks), and at withdrawal from the investigational product.
statistical analysis
The primary analysis was based on observed data using the intent-to-treat (ITT) population, with patients analyzed in the group to which they were randomized, regardless of later crossover. All available HRQOL records collected at scheduled or discontinuation visits were included in the analysis until patients withdrew from the study. Changes from baseline in the HRQOL scores were analyzed by parametric analysis of covariance at each time point using baseline as a covariate, as prespecified in the protocol. To account for missing data, the change from baseline analysis was also carried out using the last observation carried forward (LOCF) approach. In this approach, missing HRQOL scores from scheduled visits were imputed from the last nonmissing score at a previous visit. To get an overall test of treatment effects over the first 6 months, a repeated measures analyses using linear models with an autoregressive covariance structure, which accounts for within-patient correlation, was implemented.
A sensitivity analysis was carried out to explore the effect on the health outcome analysis of the 73 patients who were randomized to lapatinib monotherapy and crossed over to combination therapy after disease progression. For this analysis, HRQOL records were included up to patient withdrawal from the original randomized treatment. For patients in the same treatment through the study, the HRQOL data inclusion criteria were the same as in the primary analysis. For crossover patients, HRQOL records were included only if collected before the crossover.
In an exploratory analysis, time to deterioration in HRQOL was also compared between the treatment arms. HRQOL deterioration was defined as the lower bound of MID decreases in HRQOL scores: 2 points for BCS, 7 points for the FACT-B total score, and 5 points for the FACT-G and the TOI scores. Patients without baseline HRQOL scores were not included in this analysis; patients without a postbaseline HRQOL assessment were treated as censored observations at the time of the baseline assessment.
Patients who did not experience documented deterioration in HRQOL were treated as censored observations at the time of the last HRQOL assessment. A sensitivity analysis, including the earliest disease progression after last HRQOL assessment as a MID event to address the possible bias caused by informative censoring, was also conducted. Kaplan-Meier methodology was used to estimate the median time to deterioration in HRQOL. The Brookmeyer and Crowley [25] method was used to calculate 95% CIs. Estimation of the HR was determined using a Cox model stratified for hormone receptor and visceral disease status, following the randomization scheme. An HR of 1 indicates that there is no difference between two arms in the rate of deteriorating HRQOL. An HR <1 indicates that the time to deterioration in HRQOL is longer for patients in the L+T arm than for the patients in the L arm.
results patients and completion rate of HRQOL assessments
The ITT population in study EGF104900 included 296 patients (148 in each treatment arm). The number of patients with FACT-B assessments at scheduled and withdrawal visits is provided in Table 1 ; percentages are shown based on patients who were still on study (i.e. excluding those that had progressed, were censored for progression or withdrawal from treatment and hence not required to complete the assessments at future visits). Of those patients who were randomized, 95% in each arm completed a baseline health outcome questionnaire. The two treatment arms had a comparable number of patients completing the questionnaire at each visit. HRQOL questionnaire completion rates over the first 6 months of follow-up varied from 66% to 96%. After 6 months, <30 patients were on study in each arm.
analysis of HRQOL change from baseline
On average, patients in the two treatment arms had comparable baseline values in all the subscale scores and total scores ( Table  2 ). Because HRQOL assessments were stopped at treatment termination or disease progression, few patients were on study and completed the questionnaire after week 24; results reported here include visits up to week 24 and the withdrawal visit.
Changes from baseline subscale scores data are summarized in Table 3 . Adjusted mean changes from baseline in the FACT-B, FACT-G, TOI, and BCS over 24 weeks of follow-up are shown in Figure 1 . In both treatment arms at all scheduled n, number of patients whose overall item response rate was >80% for the FACT-B total score, FACT-G score, and TOI score; SD, standard deviation.
original article Annals of Oncology follow-up visits, average scores were slightly lower than baseline for PWB, FWB, and SWB and stable for EWB and the BCS. Although average scores were slightly lower for patients in the L arm, both groups had overall stable HRQOL scores over 24 weeks ( Figure 1A-C) . The differences between the treatment arms ranged from 0.0 to 4.1 (FACT-B), 1.0 to 4.0 (FACT-G), and 0.5 to 2.7 (TOI) in favor of the L+T arm. The greatest differences between the treatment arms for three scores were observed at week 12 and did not reach MIDs. The difference between treatment arms in the adjusted mean changes from baseline were generally not statistically significant, with the exception of the FACT-G at week 12 (delta = 4.0, P = 0.037).
Overall, the LOCF analysis yielded results comparable with the primary analysis, data not shown; reported previously [18] . One noticeable difference between the two analytic approaches occurred at week 16 when the primary analysis showed little difference on HRQOL scores between the treatment arms but in the LOCF analysis, the magnitude of the treatment difference favored the L+T arm. A possible reason for the difference is that between week 12 and week 16, more patients in the L arm than the L+T arm progressed or withdrew from the study (L arm, 24 patients; L+T arm, 8 patients). These data indicate that during the first 24 weeks of treatment, average change from baseline in HRQOL was not meaningfully different between patients in the L+T arm and those in the L arm. In addition to the analyses at each individual time point, repeated measures analyses also revealed that during the first 6 months, the changes in HRQOL were not statistically significant between two treatment arms (FACT-B, P = 0.12; FACT-G, P = 0.10: TOI, P = 0.06). At the withdrawal visit, treatment arms had comparable decreases from baseline in adjusted mean for FACT-B (L+T, 27.9 points; L, 27.5 points), FACT-G (L+T, 27.9 points; L, 27.2 points) and TOI (L+T, 25.1; L, 25.1), and all reached MID, indicating worsening of HRQOL as disease progressed.
sensitivity analysis of HRQOL change from baseline
In this sensitivity analysis, HRQOL records were included up to patient withdrawal from the original randomized treatment. Adjusted mean changes from baseline FACT-B, FACT-G, TOI, and BCS over 24 weeks of treatment are shown in Figure 2 . Compared with the analysis in which patients were included during the crossover phase, Figure 2 reveals better HRQOL outcomes for patients in the L arm after the week 4 visit compared with the L arm in the analysis in which patients were included during the crossover.
In the primary analysis, patients on L had declining HRQOL at all the scheduled visits, which were significantly different from the combination arm at week 12 for the FACT-G score only. In this analysis, with HRQOL records after crossover excluded, patients on lapatinib monotherapy had favorable improvements from baseline at week 16 on all three scores. However, none of the treatment differences were statistically significant. At the withdrawal visit, results for all three scores and the BCS were comparable between arms.
Overall, this sensitivity analysis yielded results that were consistent with the previous analysis. Comparisons of FACT-B total score, FACT-G score, TOI score, and BCS in terms of change from baseline revealed no statistically significant differences between the L+T arm and L arm when the HRQOL records collected after the crossover were excluded from the analysis.
time to HRQOL deterioration
Results for time to deterioration in FACT-G are summarized in Table 4 and Changes >0 reflect an increased subscale score relative to baseline, whereas changes <0 reflect a worse well-being relative to baseline. a Quality-of-life data only up to date of crossover were included in the analysis. n, number of patients who answered >50% of the items in the subscale; SD, standard deviation. Time-to-deterioration analysis in other HRQOL scores showed a similar pattern (Table 5 ). Patients on L+T had longer time to deterioration than patients on L for FACT-B (HR, 0.82; 95% CI 0.56-1.20) and TOI (HR, 0.79; 95% CI 0.55-1.14) scores. For the BCS scale, the time to deterioration was comparable in two treatment arms (HR, 1.02; 95% CI 0.69-1.52). The differences between the two treatment arms in time to deterioration were not statistically significant.
Annals of
As there was evidence that patients with disease progression were more likely to experience the MID decline in HRQOL, a sensitivity analysis of time to deterioration, including the earliest disease progression after last HRQOL assessment as a MID event, was conducted. The analysis yielded similar results (FACT-G: HR, 0.81; FACT-B: HR, 0.84; TOI: HR, 0.79; BCS: HR, 0.97).
discussion
Lapatinib is the only therapy other than trastuzumab specifically approved for treating patients with HER2-positive MBC and is emerging as an effective treatment for trastuzumab-resistant disease [26] . While it is not uncommon for oncologists to continue patients on trastuzumab beyond progression, partly due to the limited treatment options, only recently have studies started evaluating the efficacy of this practice [10, 21, 22] . While the mechanism for trastuzumab resistance and how to overcome it remains under study, it appears that combination therapy enhances the effect of continuing trastuzumab. Study EGF104900 demonstrated that the addition of lapatinib to trastuzumab, a chemotherapy-free combination, provided clinical benefit to patients with HER2+ MBC [21, 22] .
The analyses presented in this paper showed that HRQOL was generally stable in both arms during the first 6 months of treatment. Comparisons of change from baseline in FACT-B, FACT-G, and TOI scores indicated slightly more favorable HRQOL results for the lapatinib plus trastuzumab patients than for patients taking lapatinib monotherapy. However, the HRQOL differences did not reach MID and most were not statistically significant at individual time points or overall. Results suggest that despite multiple lines of prior chemotherapy and trastuzumab, comparable HRQOL was maintained in both arms during the investigational treatment period. The sensitivity analysis on HRQOL records up to patient withdrawal from the original randomized treatment yielded similar results; treatment differences remained statistically and clinically insignificant. Exclusion of the HRQOL records collected after disease progression and crossover gave generally higher HRQOL scores in a smaller number of patients on monotherapy than in the primary analyses; patients who stayed in the study were generally healthier and had better HRQOL. This explains the higher HRQOL scores in the L arm at later visits in the sensitivity analyses. As more patients progressed and dropped out from the L arm or crossed over to combination therapy, analyses were possibly biased against the L+T arm. original article
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Patients who have improvement in symptoms during treatment could be considered to have a therapeutic improvement. In the case of adding an additional agent to a treatment regimen, therapeutic benefit can also be defined as improved efficacy without an attendant decline in other aspects of the patient's health. The time-to-deterioration analysis showed a pattern of longer time with stable HRQOL on all scores for patients receiving lapatinib plus trastuzumab than for patients receiving only lapatinib. Although the differences between arms were not statistically significant, the magnitude of effect was similar to that in the analysis of PFS, i.e. 4 weeks difference in time to FACT-G decline and 3.9 weeks difference in median PFS. In addition, average MID declines in HRQOL in both treatment arms at the withdrawal visit indicated clinically meaningful worsening of HRQOL as disease progressed. With these results combined, the study indicates that the delay of disease progression in this clinical trial was accompanied by a delay in HRQOL deterioration.
One limitation of this study is that HRQOL assessments were not required after disease progression. To examine the influence of missing data on results, the change from baseline analysis was repeated using the LOCF approach. For the timeto-deterioration analysis, the missing HRQOL data after progression resulted in censoring of approximately half the patients in each arm before reaching the MID decline. To address the possibility of informative censoring, a sensitivity analysis that treated both HRQOL declines and progression as events was conducted, with similar results.
In conclusion, this analysis demonstrated that the HRQOL was comparable for these heavily pretreated patients receiving combination or monotherapy lapatinib. Lapatinib in combination with trastuzumab prolonged PFS and may improve or maintain near-terminal HRQOL, suggesting a meaningful clinical benefit to patients.
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